Blaise Coleman - Mar 29, 2022 Form 4 Insider Report for Endo International plc (ENDPQ)

Signature
/s/ Matthew J. Maletta, by power of attorney
Stock symbol
ENDPQ
Transactions as of
Mar 29, 2022
Transactions value $
-$46,806
Form type
4
Date filed
3/31/2022, 04:02 PM
Previous filing
Mar 8, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ENDPQ Ordinary Shares Tax liability -$21.3K -8.44K -2.08% $2.52* 396K Mar 29, 2022 Direct F1, F2, F3
transaction ENDPQ Stock Incentive Plan Performance Share Units Options Exercise $0 -89.7K -6.26% $0.00 1.34M Mar 30, 2022 Direct F4, F5, F6
transaction ENDPQ Ordinary Shares Options Exercise $0 +35.9K +9.06% $0.00 432K Mar 30, 2022 Direct F4, F7
transaction ENDPQ Ordinary Shares Tax liability -$25.5K -10.1K -2.35% $2.52* 422K Mar 30, 2022 Direct F3, F4, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Thirty-three and one-third percent (33 1/3%) of Mr. Coleman's March 29, 2019 grant of restricted stock units (RSUs) vested on March 29, 2022.
F2 These shares represent stock withheld by Endo International plc to satisfy Mr. Coleman's tax withholding obligations on shares acquired upon vesting of RSUs.
F3 Represents the vesting price which is the average of the high and low share price on March 29, 2022.
F4 On March 30, 2022, based on performance against target levels with respect to Mr. Coleman's March 29, 2019 grant of performance share units, these awards were released and the performance share units were converted into 35,910 ordinary shares. Of this amount, 10,137 ordinary shares were withheld by Endo International plc to satisfy Mr. Coleman's tax withholding obligations on shares acquired upon vesting, with the remainder transferred to Mr. Coleman.
F5 Represents the target number of shares issuable upon Endo International plc's achievement of both: (a) shareholder return performance metrics over a cumulative three-year period and (b) free cash flow performance metrics over a cumulative three-year period, each as determined by Endo International plc's Board of Directors at the end of such periods.
F6 These securities were granted to Mr. Coleman in consideration of his services as a senior executive of Endo International plc.
F7 This represents the automatic conversion of performance share units granted to Mr. Coleman on March 29, 2019 to ordinary shares of Endo International plc pursuant to the terms of the underlying award agreement.
F8 These shares represent stock withheld by Endo International plc to satisfy Mr. Coleman's tax withholding obligations on shares acquired upon vesting of performance share units.